Yang P et al. found that the use of liraglutide could ameliorate NAFLD in diabetic mice through the activation of the IRS/PI3K/Akt signaling pathway (Yang et al., 2019). The gene discussed is AKT1; the disease is metabolic dysfunction-associated steatotic liver disease.